Arbutus Biopharma Corporation logo

Arbutus Biopharma Corporation

NASDAQ:ABUS

Overview | Financials
Company Name Arbutus Biopharma Corporation
Symbol ABUS
Currency USD
Price 4.47
Market Cap 843,855,540
Dividend Yield 0%
52-week-range 1.69 - 4.72
Industry Biotechnology
Sector Healthcare
CEO Mr. William H. Collier
Website https://www.arbutusbio.com

An error occurred while fetching data.

About Arbutus Biopharma Corporation

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits

Related Stocks

Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc.

OTLK

6.47 USD

Mind Medicine (MindMed) Inc. logo

Mind Medicine (MindMed) Inc.

MNMD

6.45 USD

Kodiak Sciences Inc. logo

Kodiak Sciences Inc.

KOD

2.71 USD

Arcellx, Inc. logo

Arcellx, Inc.

ACLX

76.89 USD

Rigel Pharmaceuticals, Inc. logo

Rigel Pharmaceuticals, Inc.

RIGL

13.7 USD

Regencell Bioscience Holdings Limited logo

Regencell Bioscience Holdings Limited

RGC

5.4 USD

Belite Bio, Inc logo

Belite Bio, Inc

BLTE

48.82 USD

Athira Pharma, Inc. logo

Athira Pharma, Inc.

ATHA

0.528 USD

Financials

Numbers are in millions USD

Numbers are in millions USD